The cash balance was getting low again, my view is that by drawing down on the new loan provides MSB with enough funds to get them to an inflection point like FDA approval and provides them more muscle in negotiations with potential partners. The next six months will be very telling for MSB. We will wait and see.
Add to My Watchlist
What is My Watchlist?
